Shield Therapeutics plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anders Lundstrom
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Northern Design Centre Gateshead United Kingdom NE8 3DF
- IPO Date
- Dec 6, 2019
- Website
- shieldtherapeutics.com
- Similar Companies
- Business
- Shield Therapeutics plc is a United Kingdom-based commercial-stage specialty pharmaceutical company focused on the development, manufacturing, and commercialization of innovative pharmaceuticals for the treatment of iron deficiency with or without anemia. Founded in 2015 and headquartered in Gateshead, England, Shield's principal product is ACCRUFeR® (ferric maltol), a novel, stable, non-salt based oral therapy broadly indicated for adults suffering from iron deficiency across multiple therapeutic categories. The company markets ACCRUFeR® under the brand names Accrufer® in the United States and Feraccru® in Europe, with the product approved in major markets including the US, European Union, UK, Canada, Australia, and Switzerland. Shield operates through subsidiaries including Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited, and holds exclusive license agreements for the development and commercialization of ACCRUFeR® in China, Hong Kong, Macau, Taiwan, and the Republic of Korea. In recent developments, Shield Therapeutics reported significant growth in prescription sales and revenues for ACCRUFeR®, generating $32.3 million in total revenues for the year ended December 31, 2024, representing a 146% increase over the prior year. The company made substantial progress in expanding global patient access and strengthened its balance sheet with a $10 million equity funding round completed in early 2025, led by its largest shareholder AOP Health International Management AG. Shield also realigned its US sales team in late 2024 to focus on territories with the highest potential and maintained active development programs including partnerships for Canada, Korea, China, and a pediatric indication. The company aims to achieve positive cash flow by the end of 2025, supported by revenue growth and operational cost savings. Shield Therapeutics primarily serves patients with iron deficiency, targeting healthcare markets in North America, Europe, and parts of Asia through licensing and direct commercialization. Its business segments encompass specialty pharmaceuticals with a focus on iron deficiency therapies. Shield Therapeutics’ innovative approach addresses a significant unmet need in iron deficiency treatment with a proprietary oral formulation designed to improve patient outcomes and tolerability. This latest strategic expansion, financial strengthening, and focus on global commercialization reinforce Shield Therapeutics’ position as a specialized pharmaceutical company dedicated to iron deficiency treatment innovation.
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
Shield shares jump after FDA extends Accrufer exclusivity
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
Shield Therapeutics shares positive efficacy data for iron deficiency treatment
Shield Therapeutics lifted as US FDA extends Accufer approval
Shield Therapeutics shares surge 21% as ACCRUFeR revenues double
Shield Therapeutics rises on Japan licensing deal for iron deficiency drug
Shield Therapeutics edges closer to profitability as US sales surge
Shield Therapeutics shares rise on the back of $10m fundraiser
Shield Therapeutics unveils premium fundraiser
Shield Therapeutics ‘on track for 2024' - analyst
Shield Therapeutics up 27% after impromptu trading update
Shield Therapeutics on course in China as sales growth continues
Shield Therapeutics on track after strong quarter as it looks to raise $10m in new investment
Shield Therapeutics shares up 8% after phase III success
Shield Therapeutics hails paediatric phase III study success
Shield Therapeutics is enjoying significant growth for its iron deficiency product - ICYMI
Shield Therapeutics growth 'encouraging', says broker